• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, March 17, 2026
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

EssilorLuxottica owns 99.7% of GrandVision, paving way for delisting

by Myles Hume
December 13, 2021
in Business, Company updates & acquisitions, International, Local, News
Reading Time: 2 mins read
A A
EssilorLuxottica is expected to increase its retail footprint by around 7,000 stores across 40 countries.

EssilorLuxottica is expected to increase its retail footprint by around 7,000 stores across 40 countries.

Share on FacebookShare on Twitter

EssilorLuxottica has announced it now holds an almost 100% stake in GrandVision after the completion of a mandatory public offer period, opening the door to delist shares in the optical retailer on the Amsterdam Stock Exchange.

In a statement on 6 December, the Franco-Italian eyewear giant said it has completed the acceptance period for GrandVision shareholders to tender their shares, resulting in EssilorLuxottica obtaining an additional 13.06% of the outstanding GrandVision shares.

In addition to shares EssilorLuxottica secured in the original acquisition of a majority stake held by the Dutch investment firm HAL Holding, EssilorLuxottica now holds a total interest of 99.73%.

The GrandVision takeover is set to see EssilorLuxottica drastically increase its retail footprint by around 7,000 stores across 40 countries, and an additional 37,000 staff.

Although not linked to the deal, in Australia and New Zealand Luxottica operates under four retail banners: OPSM and Laubman & Pank (optical), Sunglass Hut (a dedicated sunglasses business), and Oakley (sunglasses, apparel, fashion and accessories). It has more than 600 storefronts, 300 head office employees and more than 4,500 store staff.

With EssilorLuxottica now holding more than a 95% interest in GrandVision, it revealed it now intends to delist the shares on Euronext Amsterdam “as soon as possible under the applicable rules”.

In the meantime, remaining GrandVision shareholders who have not tendered their shares during the acceptance period will have the opportunity to tender their shares under the same terms until 20 December 2021.

“These steps [to delist] are likely to have significant consequences for shareholders who do not tender their shares under the offer,” EssilorLuxottica stated.

More reading

Luxottica’s premiumisation plans

EssilorLuxottica completes GrandVision deal

Luxottica joins KeepSight; over half of optometry now registered

Tags: AcquisitionEssilorEssilorLuxotticaGrandVisionHAL HoldingLuxottica

Related Posts

Optos ultra-widefield imaging will be on show at events in Western Australia and NSW. Image: Prime Creative Media.

Optos technology on show in upcoming events

by Staff Writer
March 16, 2026

Optos is encouraging eyecare professionals serious about advancing patient care and staying ahead in eye health technology to visit its...

The eye drops can quickly relieve tired, red eyes. Image: LimeSky/stock.adobe.com.

B+L announces launch of Lumify eye drops in Australia

by Staff Writer
March 16, 2026

Bausch + Lomb (B+L) has announced the Australian launch of Lumify redness reliever eye drops in April. The Lumify range...

Dry eye can be exacerbated or even present for the first time after cataract surgery. Image: Pormezz/stock.adobe.com

Dry Eye Society announces Melbourne launch event

by Staff Writer
March 16, 2026

The Dry Eye Society (DES) has announced its official Melbourne launch event, bringing together eye care professionals with a shared interest...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited